Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatmentReport as inadecuate




Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment - Download this document for free, or read online. Document in PDF available to download.

Molecular Cancer

, 13:30

First Online: 20 February 2014Received: 07 September 2013Accepted: 12 February 2014DOI: 10.1186-1476-4598-13-30

Cite this article as: Wang, YY., Zhe, H. & Zhao, R. Mol Cancer 2014 13: 30. doi:10.1186-1476-4598-13-30

Abstract

Solid cancer remains a major cause of death in the world. As limited treatment options are currently available to patients with solid cancer, novel preventive control and effective therapeutic approaches are considered to be reasonable and decisive measures to combat this disease. The plant-derived triterpenoids, commonly used for medicinal purposes in many Asian countries, poses various pharmacological properties. A large number of triterpenoids exhibit cytotoxicity against a variety of cancer cells, and cancer preventive, as well as anticancer efficacy in preclinical animal models. To improve antitumor activity, some synthetic triterpenoid derivatives have been synthesized, including cyano-3,12-dioxooleana-1,911- dien-28-oic CDDO, its methyl ester CDDO-Me, and imidazolide CDDO-Im derivatives. In this review, we will critically examine the current preclinical evidences of cancer preventive and therapeutic activity about one of the synthetic triterpenoids, CDDO-Me. Both in vitro and in vivo effects of this agent and related molecular mechanisms are presented.

KeywordsTriterpenoid CDDO-Me Solid cancer Prevention Treatment Mechanisms  Download fulltext PDF



Author: Yan-Yang Wang - Hong Zhe - Ren Zhao

Source: https://link.springer.com/







Related documents